Integrative transcriptomic and machine learning analyses identify HDAC9 as a key regulator of mitochondrial dysfunction and senescence-associated inflammation in diabetic nephropathy.
Source check: Source checked. Not independent scientific confirmation.
Finding: Machine learning selected five diabetic-nephropathy genes; external datasets, single-cell data and HDAC9 perturbation assays support a specific mechanistic candidate.
Technology: Integrated transcriptomics and learned feature selection are tested against external datasets and cell assays, including HDAC9 knockdown.
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
- AI contribution
- Integrated transcriptomics and learned feature selection are tested against external datasets and cell assays, including HDAC9 knockdown.
- Test and result
- Evidence supports an HDAC9-associated molecular result; no claim of patient-level causal effect or therapeutic benefit.
- Limitation / still unknown
- Primary Results describe the specific comparator, cohort or experimental check; limitations are stated narrowly.
Evidence sources and annotation context
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
Evidence sources: https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1627173/full · https://europepmc.org/article/MED/40948769 · https://pubmed.ncbi.nlm.nih.gov/40948769/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..
No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.
Editorial assessment: Impact 2/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.